Major Depressive Disorder (MDD) Clinical Trials in Chicago, Illinois

4 studies are recruiting for major depressive disorder (mdd) in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

    In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo l…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Draig Clinical Site, Chicago, Illinois
    Locations
    23 in total
    Run by
    Draig Therapeutics Ltd

    See if you can join NCT07610473 on ClinicalTrials.gov

  2. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more …

    Stage
    Phase 3
    Ages
    18 to 85
    Site
    Rush University, Chicago, Illinois
    Locations
    69 in total
    Run by
    Cybin IRL Limited

    See if you can join NCT06793397 on ClinicalTrials.gov

  3. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

    The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are: Does TNX-102 SL improve depression symptoms according to a depr…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Chicago Research Center, Chicago, Illinois
    Locations
    25 in total
    Run by
    Tonix Pharmaceuticals, Inc.

    See if you can join NCT07621237 on ClinicalTrials.gov

  4. Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

    The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Vanda Investigational Site, Chicago, Illinois
    Locations
    38 in total
    Run by
    Vanda Pharmaceuticals

    See if you can join NCT06830044 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.